Distinguished in Chronic Myelogenous Leukemia (CML)

Qifa F. Liu

1838 Guangzhou Avenue, 
Guangzhou, CN 
Distinguished in Chronic Myelogenous Leukemia (CML)
1838 Guangzhou Avenue, 
Guangzhou, CN 
OverviewLocationsClinical Research

Overview

Qifa Liu practices in Guangzhou, China. Liu is rated as a Distinguished expert by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). Their top areas of expertise are Graft Versus Host Disease (GvHD), Leukemia, Chronic Graft Versus Host Disease (cGvHD), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 280 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 13 articles in the study of Chronic Myelogenous Leukemia (CML).

Locations

1838 Guangzhou Avenue, Guangzhou, China
Other Locations
No.1838 North Guangzhou Avenue, Guangzhou, 510515, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Drugs: Azacitidine, Pevonedistat
Study Phase: Phase 3
Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation
Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: April 08, 2022
Intervention Type: Drug, Radiation
Study Drugs: Busulfan, Cyclophosphamide
Study Phase: Phase 3
Granulocyte Colony-stimulating Factor+Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Granulocyte Colony-stimulating Factor+Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Minimal Residual Disease-directed Therapy for Low-risk and Intermediate-risk Acute Myeloid Leukemia.
Minimal Residual Disease-directed Therapy for Low-risk and Intermediate-risk Acute Myeloid Leukemia.
Enrollment Status: Completed
Publish Date: March 04, 2020
Intervention Type: Combination product
Study Phase: Phase 2/Phase 3
Idarubicin+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Intermediate-risk Acute Myeloid Leukemia Undergoing Autologous Hematopoietic Stem Cell Transplantation
Idarubicin+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Intermediate-risk Acute Myeloid Leukemia Undergoing Autologous Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: March 03, 2020
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Minimal Residual Disease-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allogenetic Hematopoietic Stem Cell Transplantation
Minimal Residual Disease-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allogenetic Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: February 25, 2020
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
Sorafenib for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3-ITD Positive Acute Myeloid Leukemia
Sorafenib for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3-ITD Positive Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: August 26, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

279 Total Publications

Pediatric-inspired regimen abrogates the poor prognosis of adult early T-cell precursor acute lymphoblastic leukemia.
Pediatric-inspired regimen abrogates the poor prognosis of adult early T-cell precursor acute lymphoblastic leukemia.
Journal: Leukemia & lymphoma
Published: October 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 30 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile